Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PL-doxorubicin vs Epirubicin in DLBCL
NCT03022123Unknown
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Nov 2016
- Primary completion
- Nov 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised trial of doxorubicin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Overall Response Rate up to 19 months. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03022123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022123.